Novavax, Inc. (NVAX)
NASDAQ: NVAX · Real-Time Price · USD
10.02
-0.10 (-0.99%)
Sep 2, 2026, 11:08 AM EDT - Market open
Novavax Employees
Novavax had 749 employees as of December 31, 2025. The number of employees decreased by 203 or -21.32% compared to the previous year.
Employees
749
Change (1Y)
-203
Growth (1Y)
-21.32%
Revenue / Employee
$552,465
Profits / Employee
-$330,748
Market Cap
1.65B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Ascentage Pharma Group International | 828 |
| Innoviva | 159 |
| Maze Therapeutics | 141 |
| Absci | 140 |
| Bicara Therapeutics | 103 |
| Tyra Biosciences | 87 |
| ArriVent BioPharma | 77 |
| Avalyn Pharma | 55 |
NVAX News
- 5 days ago - Novavax’s partners approved for Nuvaxovid formulation for vaccination season - TheFly
- 5 days ago - Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season - PRNewsWire
- 5 days ago - US FDA approves updated COVID vaccines for 2026-27 season - Reuters
- 27 days ago - Novavax Earnings Call Transcript: Q2 2026 - Transcripts
- 27 days ago - Novavax Quarterly report: Q2 2026 - Filings
- 27 days ago - Novavax Earnings release: Q2 2026 - Filings
- 27 days ago - Novavax Slides: Q2 2026 - Filings
- 27 days ago - Novavax reports Q2 EPS (32c), consensus (38c) - TheFly